Mary Sartor

Hawkesbury Road
Westmead, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Journal: Blood advances
Published: June 29, 2026

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

Journal: International journal of molecular sciences
Published: June 20, 2025

Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.

Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.

Journal: Leukemia
Published: May 26, 2025

Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.

Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.

Journal: Clinical lymphoma, myeloma & leukemia
Published: December 10, 2024

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.

Journal: Leukemia
Published: August 26, 2022

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.

Journal: Pediatric blood & cancer
Published: October 25, 2021

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.

Journal: Cancers
Published: September 30, 2021

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Journal: JAMA
Published: March 02, 2021

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Journal: Cytometry. Part B, Clinical cytometry
Published: June 03, 2016

Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping.

Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping.

Journal: Cytometry. Part B, Clinical cytometry
Published: July 25, 2014

Transforming growth factor beta (TGFβ) plays a crucial role in prolonging allograft survival in an allodepletion ("pruning") skin transplant model.

Transforming growth factor beta (TGFβ) plays a crucial role in prolonging allograft survival in an allodepletion ("pruning") skin transplant model.

Journal: Transplant immunology
Published: December 23, 2013

Alterations in chemokine receptor CCR5 expression on blood dendritic cells correlate with acute graft-versus-host disease.

Alterations in chemokine receptor CCR5 expression on blood dendritic cells correlate with acute graft-versus-host disease.

Journal: Transplantation
Published: August 02, 2013
Showing 1-12 of 13

Last Updated: 09/26/2026